The development of new treatment options for Neuropsychiatric diseases is a key priority for Boehringer Ingelheim, evidenced by the innovative work in these areas of both its collaboration partners and the Company’s own highly experienced research and development professionals.

**Indications:**
Neuropsychiatric diseases including:
- Alzheimer’s disease (focus: cognitive impairment and other neuropsychiatric symptoms)
- Schizophrenia (focus: negative symptoms and/or cognitive impairment)
- Depression (focus: treatment-resistant depression)
- Impulse control disorders.

**Specific partnering priorities:**
- Novel approaches to modulate fundamental mechanisms and pathways involved in synaptic dysfunction and maladaptive brain circuitry as the root causes of various neuropsychiatric symptom domains; ideally, the proposed modality will include a target engagement and/or pharmacodynamic marker
- Complementary non-drug approaches (e.g. cognitive remediation).

In all these areas, we are looking for compounds and concepts from early drug discovery to pre-clinical and early clinical stages.

**Out of scope:**
- Neuroprotective agents
- Monoamine uptake inhibitors or monoamine receptor modulators
- Compounds with unknown mechanism of action.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

**Working together for better health**

For more information please contact our BD&L team:
Klaus D. Mendla, PhD
klaus.mendla@boehringer-ingelheim.com

Laura Corradini, PhD
laura.corradini@boehringer-ingelheim.com